A Phase IIb, Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Second- or Third-line Treatment of Subjects with Unresectable Pleural or Peritoneal Malignant Mesothelioma

Diseases and Conditions Researched


What is the purpose of this trial?

This is a Phase 2, randomized, double-blind, parallel-group study. Subjects with unresectable pleural or peritoneal malignant mesothelioma will be randomized in a 2:1 ratio to receive either tremelimumab or placebo. Approximately 180 subjects will be enrolled at study centers in multiple countries. The study consists of a screening period, a treatment period, and a 90-day follow-up period.

Participation Guidelines

Age: Any

Click here for detailed participation information for this trial.

Sponsor: MedImmune, Inc
Last Updated:
Study HIC#: 1310012807